Drug Testing, Presumptive (Drug Screen), Urine
Drug of abuse testing in urine is commonly used in healthcare, workplace and criminal settings. In the clinical setting urine drug screen (UDS) is frequently performed to evaluate treatment, monitoring compliance and identifying use of illicit drugs. Testing for drugs of abuse usually involves testing for a number of drugs, such as cocaine, opiates, barbiturates, amphetamines, benzodiazepines, cannabinoids, methadone, oxycodone, phencyclidine (PCP), and tricyclic antidepressants. The drugs tested and cut-off levels of detection are determined by a situational event or presubscribed panel choices determined by the physician.
Immunoassay methods are most commonly used for initial screening and typically used as the first-line screen test. While immunoassays offer several advantages, including easy to use, rapid turnaround time and lower costs, they often can produce false positive results, therefore any positive screen test should be confirmed by definitive testing. In additional, immunoassays are designed to detect drug classes which can give false positive results due to cross-reactivity to drug metabolites and similar compounds, which usually requires confirmation for the patient drug monitoring and adherence (compliance).
Screening assays for urine drugs of abuse are designed to detect urine drug levels above a predetermined cutoff concentration. FDA-approved immunoassays originally designated by the mandatory guidelines for federal Workplace Drug Testing Programs commonly use higher cutoffs, which may not be clinically appropriate for evaluating medication compliance for pain management patients.
- Screen for drug overdose and toxicity (medical evaluation)
- Screen for the presence of drugs of abuse for other reasons such as pre-employment screens, Department of Transportation regulations and other employment related or court required drug screens
- Useful in detecting drug abuse involving amphetamines, cocaine, marijuana, opiates and phencyclidine
This is a screening test and not a confirmatory test. There are many drugs and widely available substances that will give a false positive test for any of these drugs. Never diagnose a patient as positive for a drug based solely on a positive urine drug screen. This test has important social and legal implications. If the patient denies taking the drug or is unable to answer, always submit a specimen for confirmatory testing.
Note: Confirmatory testing is usually done by GC/MS or LC/MS.
Negative (Non-reactive) The concentrations of the drugs are generally below the following immunoassay cut-offs for the result to be considered negative: Amphetamine: 500 ng/mL Opiates: 300 ng/mL Cocaine: 300 ng/mL Phencyclidine: 25 ng/mL Marijuana: 50 ng/mL Morphine: 300 ng/mL
Urine, 30mL, minimum 10 mL, sterile screw-capped wide-mouthed container.
Rejection criteria and validity:
Concerningly, the manipulation of urine samples by the subjects under test has led to false-negative results and therefore a urine specimen validity testing (SVT) is recommended. False-negative results may arise when the urine sample is diluted, adulterated, or substituted. A valid urine specimen for drug confirmation must have creatinine between 20-400 mg/dL, specific gravity between 1.002-1.030, pH 4.5-8.0, and temperature between 90-100°C with 4 minutes of voiding. Urine specimens with the following result from the specimen validity testing (SVT) should be rejected:
Creatinine:
- >2 mg/dL and < 20 mg/dL: possibly diluted
- <2 mg/dL: possibly substituted
Specific gravity:
- >1.001 and <1.003: possibly diluted
- <1.001 or >1.020: possibly substituted
pH:
- <3 or >11: possibly adulterated
Stability
- Ambient: 2-3 days
- Refrigerated: 7 days
1-3 days.
- Pediatr Clin North Am. 2002 Apr;49(2):317-27. [PMID: 11993285]
- Clin Lab Med. 1990 Sep;10(3):493-502. [PMID: 2253446]
- Fed Pract. 2018 Apr;35(4):38-44. [PMID: 30766353]
- Pain Physician. 2011 Mar-Apr;14(2):123-43. [PMID: 21412368]
- J Addict Dis. 993;12(2):43-56. [PMID: 8476942]
- Ann Pharm Fr. 2012 May;70(3):120-32. [PMID: 22655580]
- Mayo Clin Proc. Jan 2008; 83(1): 66-76. [PMID: 18174009]
- Clin Chem. 2003;49:357. [PMID: 12600948]
- Pediatr Clin North Am. 2002 Apr;49(2):317-27. [PMID: 11993285]
- J Addict Dis. 993;12(2):43-56. [PMID: 8476942]
- Handbook of Workplace Drug Testing, Washington, DC, AACC Press, 1995.